Immunogenic Polypeptide Loop Peptide HIV-1 Epitope Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccination efforts have been unsuccessful in eliciting protective immunity, with most antibodies generated against the HIV envelope glycoprotein gp120 being non-neutralizing and having narrow neutralization profiles, limiting their effectiveness against diverse HIV strains.
Innovation Solution
A recombinant immunogenic polypeptide is designed with a loop peptide that presents the 3074 or 2219 mAb-targeted epitope of the HIV gp120 protein, using a scaffold protein like Cholera Toxin subunit B (CTB) to induce an antibody response that neutralizes heterologous HIV-1 viruses, mimicking the specificity of broadly neutralizing monoclonal antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional HIV vaccines target the V3 region of gp120, then antibodies are generated against this variable region, but the neutralization profile remains narrow and strain-specific
Solution Approach 1:
The patent creates a simplified copy of the V3 loop epitope (a short peptide sequence) and presents it on a stable scaffold protein. This copy captures the essential neutralizing epitope features while eliminating the sequence variability of the native V3 region, enabling consistent recognition across diverse HIV strains.
Solution Approach 2:
The patent modifies the epitope presentation by changing from the native variable V3 loop structure to a standardized peptide sequence (e.g., CRDQKQIIGDIRQAHC) displayed on a rigid scaffold. This parameter change from variable to fixed conformation enables consistent antibody binding across different HIV strains while maintaining neutralization activity.
2Reliability
If vaccines use the native gp120 protein or V3 loop, then the natural conformation is preserved, but the immune response is dominated by non-neutralizing antibodies due to accessibility issues
Solution Approach 1:
The patent extracts only the critical neutralizing epitope sequence from the complex gp120 protein and presents it in isolation on a scaffold. This extraction removes competing non-neutralizing epitopes from the native protein structure, directing the immune response specifically toward neutralizing antibody generation.
Solution Approach 2:
The patent displays the linear peptide epitope in a new dimensional context by presenting it on the surface of a three-dimensional scaffold protein. This spatial reorganization makes the epitope more accessible to B cells and antibodies while maintaining its neutralizing conformation, overcoming the accessibility problems of the native gp120 structure.
3Adaptability or versatility
If the V3 loop sequence is highly variable across HIV strains, then strain diversity is represented, but antibody epitopes become inaccessible or too variable for broad neutralization
Solution Approach 1:
The patent segments the variable V3 loop into its essential neutralizing core sequence and presents this conserved segment on a stable scaffold. By isolating the functionally critical epitope elements from the variable flanking regions, the vaccine achieves both cross-strain recognition and conformational consistency.
Data Source
AI summary
The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.